Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05INV
|
|||
| Former ID |
DNCL002557
|
|||
| Drug Name |
PEGPH20
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 2 | [1] | |
| Pancreatic cancer [ICD-11: 2C10] | Phase 2 | [1], [2], [3] | ||
| Gallbladder disease [ICD-11: DC11.3; ICD-10: K80-K87] | Phase 1 | [1] | ||
| Gastric adenocarcinoma [ICD-11: 2B72; ICD-9: 151] | Phase 1 | [1] | ||
| Company |
Halozyme Therapeutics San Diego, CA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hyaluronidase (HYAL) | Target Info | Modulator | [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT01839487) PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.